✦ LIBER ✦

A comorbid anxiety disorder does not result in an excess risk of death among patients with a depressive disorder

✍ Scribed by Wijnand Laan; Fabian Termorshuizen; Hugo M. Smeets; Marco P.M. Boks; Niek J. de Wit; Mirjam I. Geerlings

Book ID: 113667885
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 202 KB
Volume: 135
Category: Article
ISSN: 0165-0327
DOI: 10.1016/j.jad.2011.08.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of duloxetine in patients with an an

Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature

✍ Mancini, Michele; Perna, Giampaolo; Rossi, Andrea; Petralia, Antonino 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 348 KB

Does a coexisting anxiety disorder predi

Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression?

✍ Bradley N Gaynes; Kathryn M Magruder; Barbara J Burns; H.Ryan Wagner; Kimberly S 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 211 KB

PMH10 THE INFLUENCE OF COMORBID ANXIETY

PMH10 THE INFLUENCE OF COMORBID ANXIETY ON MEDICATION USE AND SERVICE UTILIZATION AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE

✍ C.H. Wu; J. Farley 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

How long should a trial of escitalopram

How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database

✍ David S. Baldwin; Dan J. Stein; Ornah T. Dolberg; Borwin Bandelow 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo‐controlled trials (RCTs) and to infer the optimal duration of initial

P.5.013 - Safety profile of flesinoxan;

P.5.013 - Safety profile of flesinoxan; results form a meta-analysis of studies in patients with major depressive disorder or generalised anxiety disorder

✍ J.M. de Voogd; G. Stevens 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 259 KB

Power laws in covariability of anxiety a

Power laws in covariability of anxiety and depression among newly diagnosed patients with major depressive episode, panic disorder and controls

✍ David A. Katerndahl 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB